CROMA-PHARMA is proud to share that it has successfully completed its first FDA Pre-Approval Inspection (PAI) conducted by the U.S. Food and Drug Administration.
This accomplishment represents a pivotal step in their journey to bring their innovative medical devices to the US market, reflecting their unwavering commitment to meeting the highest regulatory standards, Managing Director Andreas Prinz wrote on LinkedIn.
He shared he extends his heartfelt gratitude to the exceptional team for their dedication, expertise, and hard work in achieving this important milestone. Together, the company looks forward to embracing the opportunities ahead as they continue to advance our mission of enhancing patient care globally.
